Executive Summary Antibody–drug conjugates (ADCs) have rapidly evolved from an innovative therapeutic modality into one of the most strategically important areas in the biotech industry. In recent years, the ADC market has undergone significant changes: A surge in licensing deals and M&A activity Increasing investment from large pharmaceutical companies in ADC pipelines Growing focus among biotech startups on ADC platform technologies These trends indicate that: The ADC mark

Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottl

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen

Introduction This is the fourth article in the ADC series. If previous articles discussed: The integrated system of antibody–drug conjugates (Series I) The evolution of ADC generations (Series II) Linker and conjugation as the engineering core (Series III) This article moves upstream to a more fundamental question: ADC target selection — which antigens are biologically suitable for ADC development? This article is written for readers without prior ADC experience who want to u

This long-form article is written for readers without prior ADC expertise who want to understand why antibody–drug conjugates have become one of the most important oncology drug platforms of the 2020s. Starting from first principles, it gradually builds toward engineering trade-offs and industry strategy. Executive Summary Antibody–drug conjugates (ADCs) are designed to deliver extremely potent drugs directly into cancer cells using antibodies as targeting vehicles. ADC suc